SCHEMBL1900135

SCHEMBL1900135

COc1ccncc1C#Cc1ccc(C2(NC(=O)O)CCC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.39
CYP2E1 P05181 1/20 0.39
CYP2A6 P11509 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2B6 P20813 1/20 0.39
CYP2C19 P33261 1/20 0.39
ROCK2 O75116 2/20 0.38
ROCK1 Q13464 1/20 0.38
CHRM2 P08172 1/20 0.36
GRM5 P41594 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
POLB P06746 1/20 0.36
FFAR1 O14842 1/20 0.35
SLC6A9 P48067 2/20 0.34
MMP12 P39900 1/20 0.34
QPCT Q16769 1/20 0.33
SCN9A Q15858 1/20 0.33
HDAC3 O15379 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC2 Q92769 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1902393 0.92 ROCK2 (0.38) ROCK2ROCK1CHRM2GRM5SIGMAR1
SCHEMBL14118801 0.87 AKT1 (0.36) CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL1901967 0.81 FFAR1 (0.39) ROCK2ROCK1FFAR1PTGDR2
SCHEMBL1905298 0.79 OPRL1 (0.42) ROCK2ROCK1FFAR1
SCHEMBL1903122 0.79 ACACB (0.50) ROCK2ROCK1CHRM2GRM5SIGMAR1
SCHEMBL1903847 0.78 HDAC3 (0.35) ROCK2ROCK1CHRM2GRM5SIGMAR1
SCHEMBL1905635 0.78 ACACB (0.36) ROCK2ROCK1CHRM2GRM5SIGMAR1
SCHEMBL1908467 0.78 CYP1A2 (0.37) CYP1A2CYP2E1CYP2A6CYP2C9CYP2B6
SCHEMBL1905056 0.76 CHRM2 (0.35) ROCK2ROCK1CHRM2GRM5SIGMAR1
SCHEMBL13254923 0.75 SSTR4 (0.42) FFAR1HDAC3HDAC1HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120309739-A1 AKT / PKB INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2012-12-06 US disclosed
EP-2496566-A1 AKT / PKB INHIBITORS Almac Discovery Limited (GB) 2012-09-12 EP disclosed
WO-2011055115-A1 AKT / PKB INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309739-A1 AKT / PKB INHIBITORS AKT1, AKT2, AKT3 CYP1A2 4821/4885CYP2E1 4824/4885CYP2A6 4634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.